Dear EURETINA Members, A very warm welcome to the September 27th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »September 27th, 2024 “EURETINA-Brief”© Issue No. 300
Sept. 19th, 2024 – On the first day of the EURETINA Congress in Barcelona, Prof. Anat Loewenstein, President of EURETINA was delighted to announce the… Read More »EURETINA announce the inaugural Ramin Tadayoni Award for Dr. Andrea Govetto, MD, PhD, based in Milan, Italy.
Researchers at Nuffield Laboratory of Ophthalmology, University of Oxford and the Oxford Eye Hospital, NHS Foundation Trust, has reported that a surrogate biomarker (comprising the… Read More »Clinical trial endpoints use EZ and ELM biomarkers for selecting patients for treatments on X-linker retinitis pigmentosa.
HuidaGene Therapeutics, based in Shanghai, China and Clinton, New Jersey, have reported preliminary data on a novel gene therapy treatment for RPE-65 LCA (Leber congenital… Read More »HuidaGene Therapeutics presents a novel AAV9 RPE-65 treatment for Leber congenital amaurosis at EURETINA Congress in Barcelona.
Dear EURETINA Members, A very warm welcome to the September 9th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »September 9th, 2024 “EURETINA-Brief” Issue No. 299
Researchers at Moorfields Eye Hospital, the UCL Institute of Ophthalmology, University College London and the Shiley Eye Institute, University of California, San Diego, has reported… Read More »Variants on the TMEM216 gene suggests an under-reporting from certain ancestry cohorts on non-syndromic retinitis pigmentosa (RP).
Researchers at the Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy and the Department of Ophthalmology, University of Oslo, Norway, have published a… Read More »A systematic review of retinitis pigmentosa and its therapeutic approaches report different treatments and disorders.
Merck (NYSE: MRK) has recently announced the completion of the acquisition of Eyebiotech Limited (EyeBio), now becoming a wholly-owned subsidiary of Merck. EyeBio was founded… Read More »Merck (NYSE: MRK) and Eyebiotech Ltd (UK) completes acquisition, following a recent experimental treatment (“Restoret”) for diabetic macular edema (DME).
Dear EURETINA Members, A very warm welcome to the August 23rd, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »August 23rd, 2024 “EURETINA-Brief”© Issue No. 298
Researchers at the Department of Ophthalmology, Boston Children’s Hospital, and the Harvard Medical School, have reported that the interface of photoreceptors and RPE in Stargardt… Read More »Analysis of data from AO-SLO images on Stargardt disease patients show clear profiles of hyper-reflective bands, potentially targeted for pharmaceutical treatment.
